Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.
Using interleukin (IL)-6-deficient (IL-6(0/0) mice or wild-type mice, we investigated the controversial role of IL-6 in joint inflammation and cartilage pathology during zymosan-induced arthritis (ZIA). Monoarticular arthritis was elicited by injection of zymosan into the right knee joint cavity. Production of IL-1, tumor necrosis factor (TNF), IL-6, and nitric oxide by the inflamed knee was assessed in washouts of joint capsule specimens. Plasma corticosterone was measured using a radioimmunoassay. Proteoglycan synthesis was assessed using [35S]sulfate incorporation into patellas ex vivo. Joint swelling was quantified by joint uptake of circulating 99mTechnetium pertechnetate. Histology was taken to evaluate cellular infiltration and cartilage damage. Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels. Except for IL-6, the released amounts and time course of these mediators were comparable in the IL-6-deficient mice and the wild-type mice. Elevated plasma corticosterone levels were measured during the first day of arthritis in both strains. At day 2 of ZIA, joint inflammation (joint swelling and cell exudate) in IL-6-deficient mice was comparable with that in the wild-type mice. The marked suppression of chondrocyte proteoglycan synthesis and proteoglycan degradation were on the average higher in the IL-6-deficient mice. Together this resulted in a more pronounced proteoglycan depletion in the IL-6-deficient mice as compared with the wild-type mice during the first week of arthritis. Injection of recombinant IL-6 into the joint cavity corrected the IL-6 deficiency and significantly reduced cartilage destruction. Inflammation was more chronic in the wild-type mice, and these mice also showed a higher prevalence for osteophyte formation. In ZIA, IL-6 plays a dual role in connective tissue pathology, reducing proteoglycan loss in the acute phase and enhancing osteophyte formation in the chronic phase. The latter could be related to the more severe joint inflammation as seen in the normal (IL-6-producing) animals during the chronic phase of arthritis.
van de Loo
F A
FA
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
Kuiper
S
S
van Enckevort
F H
FH
Arntz
O J
OJ
van den Berg
W B
WB
D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology*; D003345:Corticosterone / Q000097:blood; D016207:Cytokines / Q000378:metabolism; D007270:Injections, Intra-Articular; D015850:Interleukin-6 / Q000097:blood / Q000172:deficiency* / Q000627:therapeutic use*; D007719:Knee Joint / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009569:Nitric Oxide / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects; D011509:Proteoglycans / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D015054:Zymosan / Q000633:toxicity
D016207:Cytokines; D015850:Interleukin-6; D011509:Proteoglycans; D009569:Nitric Oxide; D015054:Zymosan; D003345:Corticosterone